SOHO State of the Art Updates and Next Questions: Withdrawal Syndrome after Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI

Nighty-eight chronic myeloid leukemia (CML) patients were included in the prospective clinical study RU-SKI and discontinued tyrosine kinase inhibitor (TKI) therapy. Withdrawal syndrome (WS) was found in 41 (42%) patients with a median time of observation of 25 months. Older age and longer TKI therapy were associated with WS. We found no relation between the rate of molecular relapses and WS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Current Trial Report Source Type: research